“Guselkumab (GUS) in Psoriasis Patients With a History of Malignancy: 5-Year Safety From VOYAGE (VOY)1&2 ”, J of Skin, vol. 6, no. 2, p. s2, Mar. 2022, doi: 10.25251/skin.6.supp.2.